MiaMed's Acquisition

MiaMed was acquired by Amicus Therapeutics on July 06, 2016.

MiaMed is a biotech firm targeting cyclin-dependent kinase-like 5 (CDKL5) deficiency, a rare, genetic neurological disease for which there is no currently approved treatment.…

Articles about MiaMed's Acquisition: